KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Dat

– Late-breaking phase 3 data for KONFIDENT trial on Sunday, February 25, 2024 –

...

Related Keywords

Japan , Washington , United States , American , Maeve Oconnor , William Lumry , Markus Heckmann , Matthew Iverson , Cristine Radojicic , Sally Van Kooten , Jonathan Bernstein , James Hao , Sandra Christiansen , Andrea Zanichelli , Constance Katelaris , Henriette Farkas , Marcus Maurer , Douglash Jones , Ricardo Zwiener , Hilary Longhurst , Paulk Audhya , Emel Ayg , Sherry Danese , Julie Ulloa , Michael Smith , Danielf Soteres , Bob Geng , Shawn Czado , James Wedner , Timothy Craig , Danny Cohn , Paula Busse , Marc Riedl , Michael Manning , Vibha Desai , Anetes Grumach , Stephen Betschel , Paul Audhya , Neil Malloy , American Academy Of Allergy , Exchange Commission , Convention Center , Kalvista Pharmaceuticals Inc , Nasdaq , Kalvista Pharmaceuticals , Annual Meeting , On Demand Treatment , Hereditary Angioedema Attacks , Patient Perceptions , Associated Barriers , Maeveo Connor , Hereditary Angioedema , Refilling On Demand Therapy , Treatment Delay , Negative Impact , Delayed On Demand Treatment , Princess Ogbogu , Prophylactic Treatment , Patients Requiring Redosing , On Demand Treatment After , Placebo Controlled Phase , Christopher Yea , Vista Pharmaceuticals , Securities Litigation Reform Act , Markets ,